Models

Isomorphic Labs raises $5 billion in largest single funding round for AI drug discovery

November 20, 2026 · 3 min read

a blurry image of a blue and white background
Dirk Lach / Unsplash

Isomorphic Labs, a Google-affiliated artificial intelligence company focused on drug development, announced on November 17 that it completed a Series C funding round of $5 billion. Greenoaks and Sequoia Capital led the round, with participation from new investors including a16z. Alphabet, Google's parent company, continued its substantial investment in the company. Temasek, Thrive Capital, and MGX, existing investors, also participated in the funding.

The round sets a new record for the largest single funding in the global AI drug discovery sector. This funding came only six months after the company's previous round. In May of this year, Isomorphic Labs raised $2.1 billion in Series B funding, which at that time also set a record for the largest single funding in the global AI pharmaceutical industry. Combined with $600 million in initial external funding completed in March 2025, the five-year-old company has disclosed total funding of $7.7 billion.

Isomorphic Labs was founded by Demis Hassabis, a Nobel Prize winner in chemistry and former co-founder of Google DeepMind, in the United Kingdom. The company was spun out from Google DeepMind in 2021, with Hassabis serving as chief executive. After stepping down as CEO of Google DeepMind in August of this year, Hassabis focused on long-term artificial general intelligence strategy, the societal impact of AI, and Isomorphic Labs.

The company's core technology is a proprietary drug design engine called IsoDDE, which integrates a series of foundational simulation AI models covering multiple therapeutic areas and different drug types. The engine can explore chemical space and help research teams design, screen, and optimize molecules with ideal drug-like properties. The company has also developed proprietary agents for exploring complex biological systems and reasoning. Isomorphic Labs stated that the combination of models and agents has advanced multiple types of drug candidate pipelines. Currently, the company's internal oncology and immunology projects, as well as collaborative projects, have achieved preclinical results.

Isomorphic Labs has established research and development partnerships with major pharmaceutical companies including Novartis, Eli Lilly, and Johnson and Johnson to explore AI applications in different drug development projects. Hassabis stated in a blog post that the funding will help the company further develop foundational biological models, increase understanding of disease mechanisms, and advance the first therapeutic programs into clinical trials.

However, in contrast to the massive funding, Isomorphic Labs still faces a long path to developing marketable drugs. In January of this year, Hassabis stated at the World Economic Forum in Davos that the company expected to initiate its first clinical trials before the end of 2026, a timeline that represents a delay from the previously stated goal of the end of 2025. The core unresolved challenge in the AI drug development industry is that while AI can accelerate the discovery of drug molecules, whether these molecules can become safe and effective drugs still requires lengthy validation. Drug development must prove that a treatment can cure human disease while ensuring it does not produce significant side effects.